IDEAYA Biosciences (NASDAQ:IDYA) Posts Earnings Results

IDEAYA Biosciences (NASDAQ:IDYA) released its quarterly earnings results on Monday. The company reported ($1.30) EPS for the quarter, missing analysts’ consensus estimates of ($0.64) by ($0.66), Bloomberg Earnings reports.

IDYA stock opened at $7.19 on Wednesday. IDEAYA Biosciences has a 52 week low of $6.55 and a 52 week high of $16.90. The stock’s 50-day moving average is $7.88.

In related news, major shareholder Alexandria Venture Investments purchased 50,000 shares of the company’s stock in a transaction on Tuesday, May 28th. The shares were bought at an average cost of $10.00 per share, for a total transaction of $500,000.00. The purchase was disclosed in a legal filing with the SEC, which is available at this link.

A number of research firms have commented on IDYA. JPMorgan Chase & Co. began coverage on shares of IDEAYA Biosciences in a research report on Monday, June 17th. They set a “neutral” rating and a $15.00 price target on the stock. Citigroup began coverage on shares of IDEAYA Biosciences in a research report on Monday, June 17th. They set a “buy” rating and a $20.00 price target on the stock. Finally, Jefferies Financial Group began coverage on shares of IDEAYA Biosciences in a research report on Monday, June 17th. They set a “buy” rating and a $14.00 price target on the stock.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences, Inc, an oncology-focused precision medicine company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's product candidate in clinical development is IDE196, a protein kinase C inhibitor for genetically-defined cancers having GNAQ or GNA11 gene mutations.

Featured Story: Holder of Record

Receive News & Ratings for IDEAYA Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEAYA Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.